Works matching AU Ozcan, M.

Results: 219
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18

    Correspondence.

    Published in:
    2002
    By:
    • Liotta, Domingo;
    • Turkoz, Ayda;
    • Toprak, Huseyin I.;
    • Ersoy, M. Ozcan;
    • Gulcan, Oner;
    • Turkoz, Riza;
    • Banerjee, Amit;
    • Kumar, A. Sampath;
    • Doorey, Andrew J.;
    • Shah, Tushar;
    • Sharma, Ravindra;
    • Mehta, Himanshu;
    • Rau, Ramesh;
    • Solanki, Premchand
    Publication type:
    Letter
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44

    Phase 2 KEYNOTE‐B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B‐cell lymphoma (PMBCL).

    Published in:
    Hematological Oncology, 2023, v. 41, p. 575, doi. 10.1002/hon.3164_431
    By:
    • McDonald, A.;
    • Verburgh, E.;
    • Gotti, M.;
    • Pinto, A.;
    • Zaucha, J.;
    • Ivanov, V.;
    • Melnichenko, V.;
    • Mocikova, H.;
    • Ozcan, M.;
    • Patti, C.;
    • Farias, J.;
    • Goncalves, I.;
    • Kuchkova, O.;
    • Mayer, J.;
    • Saydam, G.;
    • Tomassetti, S.;
    • Pathiraja, K.;
    • Ryland, K.;
    • Chakraborty, S.;
    • Jurczak, W.
    Publication type:
    Article
    45

    A phase 2 study of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B‐cell malignancies: waveLINE‐006.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 564, doi. 10.1002/hon.3164_422
    By:
    • Zinzani, P. L.;
    • Mayer, J.;
    • Benjamini, O.;
    • Berkovits, A.;
    • Glimelius, I.;
    • Stevens, D.;
    • Chaudhry, A.;
    • Demir, A. M.;
    • Sanz, R. G.;
    • Kim, W. S.;
    • Li, F.;
    • Halka, J.;
    • Marin‐Niebla, A.;
    • Ozcan, M.;
    • Paszkiewicz‐Kozik, E.;
    • Santoro, A.;
    • Ren, Y.;
    • Ogbu, U.;
    • Marinello, P.;
    • Jurczak, W.
    Publication type:
    Article
    46
    47
    48
    49

    HEALTH‐RELATED QUALITY OF LIFE AMONG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) IN A PHASE 3 STUDY OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN.

    Published in:
    Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.105_2880
    By:
    • Zinzani, P. L.;
    • Raut, M.;
    • Saretsky, T.;
    • Ramchandren, R.;
    • Santoro, A.;
    • Paszkiewicz‐Kozik, E.;
    • Gasiorowski, R.;
    • Johnson, N. A.;
    • de Oliveira, J. S. R.;
    • Buccheri, V.;
    • Perini, G. F.;
    • Dickinson, M.;
    • McDonald, A.;
    • Ozcan, M.;
    • Sekiguchi, N.;
    • Giezek, H.;
    • Nahar, A.;
    • Kuruvilla, J.
    Publication type:
    Article
    50